CARDIOVASCULAR JOURNAL OF AFRICA • Vol 23, No 2, March 2012
AFRICA
77
12. K/DOQI, Clinical practical guidelines for chronic kidney disease
(CKD): Evaluation, Classification and Stratification. Kidney Disease
Outcome Quality Initiative.
Am J Kidney Dis
2002;
39
(2 Suppl):
S22–26.
13. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regard-
ing quantitation in M-mode echocardiography: results of a survey of
echocardiographic measurements.
Circulation
1978;
58
: 1072–1083.
14. Devereux RB, Alonso DR, Lucas EM, Gottlieb E, Sachs I, Reichek N.
Echocardiographic assessment of left ventricular hypertrophy: compari-
son to necropsy findings.
Am J Cardiol
1986;
57
: 450–458.
15. De Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de
Divitidis O, Alderman MH. Left ventricular mass and body size in
normotensive children and adults: assessment of allometric relations
and impact of overweight.
J Am Coll Cardiol
1992;
20
: 1251–1260.
16. Savage DD, Garrison RJ, Kannel WB, Levy D, Anderson SJ, Stokes J,
Feinlib M, Castelli WP. The spectrum of left ventricular hypertrophy in
a general population sample: the Framingham Study.
Circulation
1987;
75
: 126–133.
17. Teicholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocar-
diographic volume determinations: echocardiographic-angiopgraphic
correlations in the presence of absence in the presence of absence of
synergy.
Am J Cardiol
1976;
37
: 7–11.
18. Lu B, Song X, Dong X, Yang Y, Zhang Z, Wen J,
et al.
High prevalence
of chronic kidney disease in population-based patients diagnosed with
type 2 diabetes in downtown Shangai.
J Diabetes Complic
2008;
22
(2):
96–103.
19. Lemley KV. Diabetes and chronic kidney disease: lessons from the
Pima Indians.
Pediatr Nephrol
2008;
23
(1): 1933–1940.
20. Das Evcimen N, King GL. The role of protein kinase C activation and
the vascular complications of diabetes.
Pharmacol Res
2007;
55
(6):
498–510.
21. Reaven GM, Lithell H, Landsberg L. Hypertension and associated
metabolic abnormalities– the role of insulin resistance and the sympa-
thoadrenal system.
N Engl J Med
1996;
334
: 374–381.
22. Ritz E. Metabolic syndrome and kidney disease
. Blood Purif
2008;
26
(1): 59–62.
23. Paravivini TM, Touyz RM. NAD (P) H oxidase, reactive oxygen
species, and hypertension: clinical implications and therapeutic possi-
bilities.
Diabetes Care
2008;
31
(Suppl. 2): S170–S180.
24. Kis E, Cseprekal O, Horvath Z, Katona G, Fekete BC,Hrapka L,
et al
.
Pulse pressure velocity in end-stage renal disease: influence of age and
body dimensions.
Pediatr Res
2008;
63
(1): 95–98.
25. Minutolo R, Borrelli S, Chiodini P, Scigliano R, Bellizzi V, Cianciaruso
B,
et al.
Effects of age on hypertensive status in patients with chronic
kidney disease.
J Hypertens
2007;
25
(11): 2325–2333.
26. Laurent S, Boutouyrie P. Arterial Stiffness: a ne surrogate end point for
cardiovascular disease.
J Nephrol
2007;
20
(Suppl. 12): S45–S50.
27. Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F, for the MMKD
study group. Uric acid as a risk factor for progression of non diabetic
chronic kidney disease? The Mild to Moderate Kidney Disease
(MMKD) Study.
Exp Gerontol
2008;
43
(4): 347–352.
28. Nardi E, Cottone S, Mule G, Palermo A, Cusiman P, Cerasola G.
Influence of chronic renal insufficiency on left ventricular dias-
tolic function in hypertensives without left ventricular hypertrophy.
J
Nephrol
2007;
20
(3): 320–328.
29. Agaba El. Characteristics of type 2 diabetics presenting with end-stage
renal disease at the Jos University Hospital, Nigeria.
West Afr J Med
2004;
23
(2): 142–145.
30. Alebiosu CO, Odusan O, Familoni OB, Juiyesimi AE. Cardiovascular
risk factors in type 2 diabetic Nigerians with clinical diabetic nephropa-
thy.
Cardiovasc J S Afr
2004;
15
(3): 124–128.
31. Kanda T, Wakino S, Hayashi K, Plutzky J. Cardiovascular disease and
type 2 diabetes mellitus: Procceeding with caution at a dangerous inter-
section.
J Am Soc Nephrol
2008;
19
: 4–7.
32. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric
acid, left ventricular mass index and risk of cardiovascular disease in
essential hypertension.
Hypertension
2006;
47
(2): 195–202.
33. Ha SK, Park HS, Kim SJ, Park CH, Kim DS, Kim HS. Prevalence
and patterns of left ventricular hypertrophy in patients with predialysis
chronic renal failure.
J Korean Med Sci
1998;
13
: 488–494.
34. Aje A, Adedeyi AA, Oladapo OO, Dada A, Ogah US, Ojji DB, Falase
AD. Left ventricular patterns in newly presenting Nigerian hyperten-
sives: An echocardiographic study.
BMC Cardiovasc Disorders
2006;
6
: 4.
35. Viazzi F, Parodi D, Leoncini G, Parodi A, Falqui V, Ratto E,
et al
.
Serum uric acid and target organ damage in primary hypertension.
Hypertension
2005;
45
: 991–996.
36. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary
Transforming Growth Factor beta and the progression of chronic kidney
disease.
Am J Nephrol
2007;
27
(5): 435–440.
37. Choncol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick
DS,
et al
. Relationship of uric acid with progression of kidney disease.
Am J Kidney Dis
2007;
50
(2): 239–247.
38. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzoli,
et al.
A
role for uric acid in the progression of renal disease.
J Am Soc Nephrol
2002;
13
: 2888–2897.
